- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05650242
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors
An Non-randomized Open-label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Preliminary Efficacy of BA1106 in Participants With Advanced Solid Tumors
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Lin Shen
- Phone Number: 13911219511
- Email: doctorshenlin@sina.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 10036
- Recruiting
- Beijing Cancer Hospital
-
Contact:
- Lin Shen
- Phone Number: 13911219511
- Email: doctorshenlin@sina.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able and willing to provide written informed consent and to comply with the study protocol;
- Subject with histologically or cytologically confirmed advanced and/or metastatic solid tumors who have progressed on all standard therapies, are intolerant to Standard-Of-Care (SOC), and/or are non-amenable to SOC;
- At least one evaluable lesion in Part A and at least one measurable lesion in Part B according to RECIST v1.1;
- Able to provide the most recent archival tumor tissue samples (negotiable);
- Life expectancy >=12 weeks;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Adequate major organ function;
- Women of Childbearing Potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods;
- Men: Agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods and refrain from donating sperm.
Exclusion Criteria:
- Participants with active central nervous system (CNS) metastases causing clinical symptoms or metastases that require therapeutic intervention;
- Participants with any infection requiring intravenous therapy, or any other uncontrolled active infection, within 2 weeks prior to informed consent;
- Participants with symptomatic radiation pneumonia, radiation esophagitis, radiation colitis; extensive interstitial lung disease of both lungs, chronic obstructive pulmonary disease requiring bronchodilators or regular hormonal therapy; unhealed peptic ulcers, cirrhosis and related complications, chronic enteritis, necrotizing enteritis, gastrointestinal obstruction (except those who are relieved with treatment and have no safety risk as assessed by the investigator), gastrointestinal bleeding tendency or high risk of perforation, pancreatitis requiring treatment; arteriovenous thrombotic disease; chronic nephritis and nephrotic syndrome, within 8 weeks prior to C1D1;
- Participants with active autoimmune disease or the risk of recurrence;
- Participants with major cardiocerebral vascular disease;
- Participants with body cavity effusion requiring local treatment or determined as poorly controlled by the investigator;
- History of Stevens-Johnson syndrome, toxic epidermal necrolysis, or DIHS (drug-induced hypersensitivity syndrome);
- Participants with diseases affecting intravenous injection and venous blood collection;
- Prior use of any anti-cancer therapy (including chemotherapy, radiotherapy, targeted therapy, immunotherapy, traditional Chinese medicine, etc.) within 4 weeks, or non-antitumor traditional Chinese medicine within 2 weeks, prior to C1D1;
- Prior use of drugs targeting IL-2 receptors;
- History of being receipt of any organ transplantation or allogeneic stem-cell transplantation;
- Risk of gastrointestinal ulcers or bleeding as assessed by the investigator;
- Prior treatment with systemic immunosuppression excluding nasal/inhaled corticosteroids or physiological dosed systemic corticosteroids, within 2 weeks prior to C1D1;
- Prior treatment with cytokine, blood transfusion, or blood products within 4 weeks prior to C1D1;
- Participants with major surgical procedure or significant traumatic injury, within 4 weeks prior to C1D1; or with wound healing complications before enrolment;
- Vaccination with live vaccines within 4 weeks prior to informed consent;
- Known hypersensitivity to any of the components of BA1106;
- Participants with grade 2 or higher toxicities from any previous therapies [except for cases of alopecia and peripheral sensory neuropathy (both grade 2), which are allowed];
- Positive for Hepatitis B and C, or positive HIV test at screening;
- History of drug abuse, drug addiction, or alcoholism;
- Pregnancy, lactation, or breastfeeding;
- Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BA1106
Part A (Dose-Escalation): Mixed solid tumors participants will receive ascending doses of BA1106. BA1106 will be administered by intravenous (IV) infusion. The observation period of Dose Limiting toxicity (DLT) is 28 days, then the participants will receive BA1106 every three weeks (Q3W) until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the maximum duration of administration was no more than 2 years. Part B (Dose-Expansion): Participants of selected tumors will receive a fixed dose of BA1106 that selected according to the results of Part A once every 3 weeks (Q3W) or once every 2 weeks (Q2W), until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the maximum duration of administration was no more than 2 years. |
In part A, after the observation period of DLT (28 days), intravenous (IV) once every 3 weeks (Q3W). In Part B, intravenous (IV) once every 3 weeks (Q3W) or once every 2 weeks (Q2W). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (according to NCI CTCAE 5.0).
Time Frame: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment, up to 2 years.
|
From the initiation of study treatment to the completion of safety follow-up after the end of study treatment, up to 2 years.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the curve (AUC) of BA1106
Time Frame: up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days)
|
up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days)
|
Half-life (t1/2) of BA1106
Time Frame: up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days)
|
up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days)
|
Maximum Concentration (Cmax) of BA1106
Time Frame: up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days)
|
up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days)
|
Minimum Concentration (Cmin) of BA1106
Time Frame: up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days)
|
up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days)
|
Time of maximum concentration (Tmax) of BA1106
Time Frame: up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days)
|
up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days)
|
Clearance (CL) of BA1106
Time Frame: up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days)
|
up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days)
|
Volume of distribution at steady-state conditions (Vss) of BA1106
Time Frame: up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days)
|
up to cycle 6nd (cycle 1st is 28 days, the other cycles are 21 days)
|
Incidence and titer of Anti-Drug Antibodies (ADA) during the study relative to the prevalence of ADA at baseline
Time Frame: up to 2 years
|
up to 2 years
|
Incidence of Neutralizing Antibodies (Nab) during the study relative to the prevalence of Nab at baseline
Time Frame: up to 2 years
|
up to 2 years
|
Objective Response Rate (ORR)
Time Frame: up to 2 years
|
up to 2 years
|
Duration of Response (DOR)
Time Frame: up to 2 years
|
up to 2 years
|
Disease Control Rate (DCR)
Time Frame: up to 2 years
|
up to 2 years
|
Progression-Free Survival (PFS)
Time Frame: up to 2 years
|
up to 2 years
|
Overall Survival (OS)
Time Frame: up to 2 years
|
up to 2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BA1106/CT-CHN-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Alphamab (Australia) Co Pty Ltd.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsAustralia